jpg.jpg
Incysus Therapeutics Initiates Enrollment in Phase 1 Study of a Genetically Modified Gamma-Delta (γδ) T Cell Immunotherapy in Patients with Newly Diagnosed Glioblastoma
February 27, 2020 07:00 ET | Incysus Therapeutics, Inc.
NEW YORK, Feb. 27, 2020 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the...
jpg.jpg
Incysus Therapeutics to Present at the 2019 Society for Neuro-Oncology (SNO) Annual Meeting
November 21, 2019 07:00 ET | Incysus Therapeutics, Inc.
NEW YORK, Nov. 21, 2019 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the...
axsomelogo-468x57.jpg
Axsome Therapeutics Presents Positive AXS-07 Phase 1 Trial Results at the 19th Congress of the International Headache Society
September 05, 2019 07:00 ET | Axsome Therapeutics, Inc.
Dual mechanisms, rapid absorption and long half-life support therapeutic potential of AXS-07 in migraine AXS-07 MOMENTUM Phase 3 trial ongoing in migraine patients with history of inadequate response...
jpg.jpg
Incysus Therapeutics to Present at the BioCentury NewsMakers in the Biotech Industry Conference
September 04, 2019 07:00 ET | Incysus Therapeutics, Inc.
NEW YORK, Sept. 04, 2019 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the...
jpg.jpg
Incysus Therapeutics Appoints Rozanna Yaing As Senior Vice President, Quality And Regulatory Affairs
July 02, 2019 08:00 ET | Incysus Therapeutics, Inc.
NEW YORK, July 02, 2019 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the...
15-SORRENTO-Therapeutics-Logo-FINAL.png
Sorrento Therapeutics Updates Positive Results of Phase 1b Resiniferatoxin (RTX) in Knee Osteoarthritis Pain Trial
June 19, 2019 07:00 ET | Sorrento Therapeutics, Inc.
Forty five patients were treated with escalating doses of RTX in the Phase 1b trial to date. Thirty seven patients received RTX and eight patients received saline (pooled as placebo group).Most...
jpg.jpg
Incysus Therapeutics Announces FDA Approval of IND Application for a Novel Gamma-Delta (γδ) T Cell Therapy for Treatment of Patients With Newly-Diagnosed Glioblastoma
April 01, 2019 08:00 ET | Incysus Therapeutics, Inc.
NEW YORK, April 01, 2019 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the...
jounce.png
Jounce Therapeutics Completed Enrollment in First Cohort of Phase 1 Clinical Trial with its PD-1 Inhibitor, JTX-4014
January 03, 2019 08:00 ET | Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., Jan. 03, 2019 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...
aTyr Pharma Logo New.jpg
aTyr Pharma Announces Positive Phase 1 Data for ATYR1923 Therapeutic Candidate
June 26, 2018 08:00 ET | aTyr Pharma, Inc.
ATYR1923 Well-Tolerated at all Doses Tested, with No Significant Adverse Events Pharmacokinetic Profile Supports Potential Once-Monthly Dosing SAN DIEGO, June 26, 2018 (GLOBE NEWSWIRE) -- aTyr...
treos logo.jpg
Treos Bio Announces Activation of U.S. Clinical Trial Site for Phase 1 Study of PolyPEPI™ Precision Cancer Vaccine for Patients with Metastatic Colorectal Cancer
April 11, 2018 08:15 ET | Treos Bio Corp.
SAN FRANCISCO and LONDON, April 11, 2018 (GLOBE NEWSWIRE) -- Treos Bio Limited, an immuno-oncology company developing next-generation, off-the-shelf precision cancer vaccines coupled with companion...